Enhertu approved in US for 2L HER2+ breast cancer
05 May 2022 07:10 BST Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu to earlier use in metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or